Sun Pharma Advanced Research reports Q1 FY26 results.
Sun Pharma Advanced Research reports Q1 FY26 results. The company has released its unaudited financial results for the quarter ended June 30, 2026. Key figures include revenue of ₹128.4 crore and net profit of ₹22.1 crore. Performance reflects steady growth in core R&D operations.
📊 STOCKS: $SPARC | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Earnings
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.